NEW BRUNSWICK, N.J., Feb. 12 LAWFUEL – US Business & Law — Johnson &
Johnson today voluntarily disclosed to the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries.
The actions were contrary to the Company’s policies, and the payments may
fall within the jurisdiction of the Foreign Corrupt Practices Act. The
Company will provide additional information to DOJ and SEC, and will
cooperate with the agencies’ reviews of these matters.
Effective today, Michael J. Dormer, Worldwide Chairman, Medical Devices
& Diagnostics, has retired from the Corporation. In a letter to Johnson &
Johnson, Mr. Dormer cited the internal review of these matters and noted he had “ultimate responsibility by virtue of my position” for those
subsidiaries that were the subject of the disclosure.
Effective immediately, all worldwide businesses within the Medical
Devices & Diagnostics segment will report to Nicholas J. Valeriani,
Worldwide Chairman, Medical Devices & Diagnostics, a Company executive with nearly 30 years’ experience. Mr. Valeriani will now have responsibility for businesses previously under the management oversight of Mr. Dormer, in addition to those for which he is already responsible.
SOURCE Johnson & Johnson